Eclosion2 & Cie Société en commandite de placements collectifs

Eclosion2 is a Swiss life sciences investment fund managed by Eclosion Ventures and focused on creating and backing early-stage biotechnology companies. The fund has supported companies from seed stage through clinical proof of concept, with an emphasis on transformational therapeutics and platform technologies in areas such as multiple sclerosis, fibrosis, and oncology. Publicly described portfolio exposure includes companies such as GeNeuro and Genkyotex, indicating a strategy centered on company formation and venture investment rather than direct internal drug development. Available business registry and fund-profile sources indicate that the fund is closed and in liquidation. Accordingly, Eclosion2 should be classified as a healthcare-focused investment vehicle rather than an operating drug developer.